IAMOG
OTLK icon

Investors Asset Management of Georgia’s Outlook Therapeutics OTLK Stock Holding History

Investors Asset Management of Georgia’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-500
Closed -$3.94K – 163
2023
Q4 		$3.94K Hold
500
– – ﹤0.01% 159
2023
Q3 		$2.21K Hold
500
– – ﹤0.01% 162
2023
Q2 		$17.4K Hold
500
– – 0.01% 166
2023
Q1 		$10.9K Hold
500
– – 0.01% 168
2022
Q4 		$10.8K Hold
500
– – 0.01% 168
2022
Q3 		$12K Hold
500
– – 0.01% 447
2022
Q2 		$10K Buy
+500
New +$14.4K 0.01% 410

Other funds holding OTLK

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Investors Asset Management of Georgia's OTLK Position: Q1 2024 in Review

Investors Asset Management of Georgia sold out of Outlook Therapeutics (OTLK) in Q1 2024, closing a stake of 500 shares — an estimated $3.94K sold.

Investors Asset Management of Georgia first reported a position in OTLK in Q2 2022 and held it in 7 quarters. The position peaked at $17.4K in Q2 2023. 57 funds tracked by Wall St. Rank hold OTLK as of Q1 2024.

  • Investors Asset Management of Georgia reported no remaining Outlook Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Investors Asset Management of Georgia sold 500 Outlook Therapeutics shares in Q1 2024, an estimated $3.94K.
  • Investors Asset Management of Georgia first reported a position in Outlook Therapeutics in Q2 2022 and held it in 7 quarters.
  • Investors Asset Management of Georgia's Outlook Therapeutics position peaked at $17.4K in Q2 2023.
  • 57 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q1 2024.

Based on Investors Asset Management of Georgia's 13F filing for Q1 2024, filed 22 Apr 2024.